DexCom, Inc. $DXCM Shares Acquired by Marshall Wace LLP

Marshall Wace LLP boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 260.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,822,085 shares of the medical device company’s stock after purchasing an additional 2,762,504 shares during the period. Marshall Wace LLP owned approximately 0.97% of DexCom worth $333,630,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SWS Partners acquired a new position in shares of DexCom in the 2nd quarter worth approximately $1,661,000. Baader Bank Aktiengesellschaft bought a new position in DexCom during the second quarter worth $393,000. Jennison Associates LLC boosted its holdings in DexCom by 9.4% in the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after purchasing an additional 994,300 shares during the period. Mn Services Vermogensbeheer B.V. increased its stake in DexCom by 4.9% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock valued at $12,797,000 after purchasing an additional 6,800 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of DexCom by 85.7% during the second quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock worth $105,469,000 after purchasing an additional 557,576 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other DexCom news, Director Richard Alexander Collins sold 3,948 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $55.17, for a total transaction of $217,811.16. Following the sale, the director directly owned 37,994 shares in the company, valued at approximately $2,096,128.98. The trade was a 9.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the sale, the director directly owned 27,031 shares of the company’s stock, valued at approximately $1,569,690.17. This represents a 3.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 7,866 shares of company stock valued at $448,177. Company insiders own 0.32% of the company’s stock.

DexCom Stock Up 0.6%

Shares of DexCom stock opened at $65.25 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25. The business’s fifty day moving average price is $64.00 and its two-hundred day moving average price is $75.31. The company has a market capitalization of $25.45 billion, a P/E ratio of 36.25, a PEG ratio of 1.39 and a beta of 1.51.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same period last year, the company earned $0.45 earnings per share. The company’s quarterly revenue was up 21.6% compared to the same quarter last year. As a group, research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on DXCM shares. Truist Financial reaffirmed a “buy” rating and issued a $82.00 price target (down from $94.00) on shares of DexCom in a report on Monday, November 3rd. BTIG Research decreased their target price on DexCom from $109.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, October 31st. Weiss Ratings reiterated a “sell (d+)” rating on shares of DexCom in a research report on Monday. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 16th. Finally, Morgan Stanley upgraded DexCom from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $63.00 to $75.00 in a research note on Tuesday. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.27.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.